Compare Abeona Therapeutics Inc (ABEO) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Enbridge Inc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Enbridge Inc trades at $51.51 (market cap $112.62B). The key difference: Enbridge Inc is far larger — about 267.4× Abeona Therapeutics Inc's market cap, and Enbridge Inc pays a 5.34% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ENB | |
|---|---|---|
Market Cap | $421.19M | $112.62B |
Sector | Health | Energy |
52-Week High | $7.45 | $58.04 |
52-Week Low | $4.17 | $45.23 |
Enterprise Value | $276.10M | $196.53B |
Dividend Yield | — | 5.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Enbridge (ENB) trades at $51.39, up 0.21% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $65.2B revenue, 11.5% net margin, and consistent dividend growth spanning 31 years. Recent Q2 2026 results exceeded expectations with $0.46 EPS versus $0.43 estimate, supported by robust pipeline and utility performance. Analyst sentiment is balanced with 48% buy ratings while technical indicators show oversold conditions with RSI at 14.8.
ENB presents a compelling income opportunity with 5.3% dividend yield and $41B growth pipeline, though faces regulatory risks from Line 5 litigation and Wisconsin tribal land dispute. The stock's current valuation at 27.8x P/E appears reasonable given stable cash flows, but investors should monitor debt levels approaching 49% of assets and potential project delays affecting growth execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
